Literature DB >> 22710446

Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers.

Karina Ramirez1, Rezwanul Wahid, Charles Richardson, Robert F Bargatze, Samer S El-Kamary, Marcelo B Sztein, Marcela F Pasetti.   

Abstract

Noroviruses are the most frequent cause of acute gastroenteritis in humans of all ages. No vaccines are currently available. An intranasally delivered Norwalk (NV) virus-like particle (VLP) vaccine was recently shown to be well tolerated, immunogenic and to protect against infection in Phase 1 studies. Here, we examined B memory (B(M)) responses in volunteers who received the highest dosage levels of the NV-VLP vaccine (50 μg and 100 μg). We measured the frequency of NV-specific IgG and IgA-secreting B(M) cells in peripheral blood and the level of antibodies produced by these cells in culture. All subjects immunized with 100 μg of the NV-VLP vaccine and 90% of those who received 50 μg had significant IgA or IgG B(M) responses. The B(M) cell frequencies correlated with serum antibody levels and mucosally-primed antibody-secreting cell responses. This is the first demonstration of dose-dependent, functional B(M) responses in humans immunized intranasally with a NV-VLP vaccine.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710446     DOI: 10.1016/j.clim.2012.05.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  32 in total

1.  Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.

Authors:  Anna D Koromyslova; Jessica M Devant; Turgay Kilic; Charles D Sabin; Virginie Malak; Grant S Hansman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 2.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 3.  Norovirus.

Authors:  Elizabeth Robilotti; Stan Deresinski; Benjamin A Pinsky
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

4.  Mucosal and Cellular Immune Responses to Norwalk Virus.

Authors:  Sasirekha Ramani; Frederick H Neill; Antone R Opekun; Mark A Gilger; David Y Graham; Mary K Estes; Robert L Atmar
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

5.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 6.  Vaccine against norovirus.

Authors:  Ming Tan; Xi Jiang
Journal:  Hum Vaccin Immunother       Date:  2014-05-05       Impact factor: 3.452

Review 7.  Prospects and Challenges in the Development of a Norovirus Vaccine.

Authors:  Nicolas W Cortes-Penfield; Sasirekha Ramani; Mary K Estes; Robert L Atmar
Journal:  Clin Ther       Date:  2017-07-26       Impact factor: 3.393

8.  The state of norovirus vaccines.

Authors:  Kari Debbink; Lisa C Lindesmith; Ralph S Baric
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

9.  Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Authors:  Jackie E Mahar; Nicole C Donker; Karin Bok; Gert H Talbo; Kim Y Green; Carl D Kirkwood
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 10.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.